Learn About Sertoli-Leydig Cell Tumor
Sertoli-Leydig cell tumor (SLCT) is a rare cancer of the ovaries. The cancer cells produce and release a male sex hormone called testosterone.
Sertoli-stromal cell tumor; Arrhenoblastoma; Androblastoma; Ovarian cancer - Sertoli-Leydig cell tumor
The exact cause of this tumor is not known. Changes (alterations) in genes may play a role.
SLCT occur most often in young women 20 to 30 years old. But the tumor can occur at any age.
The Sertoli cells are normally located in the male reproductive glands (the testes). They feed sperm cells. The Leydig cells, also located in the testes, release a male sex hormone.
These cells are also found in a woman's ovaries, and in very rare cases lead to cancer. SLCT starts in the female ovaries, mostly in one ovary. The cancer cells release a male sex hormone. As a result, the woman may develop symptoms such as:
- A deep voice
- Enlarged clitoris
- Facial hair
- Loss in breast size
- Stopping of menstrual periods
Pain in the lower belly (pelvic area) is another symptom. It occurs due to the tumor pressing on nearby structures.
Surgery is done to remove one or both ovaries.
If the tumor is at an advanced stage, chemotherapy or radiation therapy may be done after surgery.
William Foulkes practices in Montreal, Canada. Mr. Foulkes is rated as an Elite expert by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Sertoli-Leydig Cell Tumor, Ovarian Cancer, DICER1 Syndrome, Oophorectomy, and Mastectomy.
Tmh Physician Associates PLLC
Pedro Ramirez is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Ramirez is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Endoscopy. Dr. Ramirez is currently accepting new patients.
Aurora Gynecologic Oncology
Scott Kamelle is an Oncologist in West Allis, Wisconsin. Dr. Kamelle is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteroscopy, and Bladder Reconstruction.
Early treatment results in a good outcome. Feminine characteristics usually return after surgery. But male characteristics resolve more slowly.
For more advanced stage tumors, outlook is less positive.
Background: \- Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in children younger than 6 years of age. Recently, it has been shown that this condition can be inherited (e.g., mutation of the DICER1 gene). Researchers are studying both clinical and genetic aspects of this newly described condition. They are interested i...
Summary: Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with ...
Published Date: June 17, 2024
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Beffa LB, Sung CJ, DiSilvestro PA. Germ cell, stromal, and other ovarian tumors. In: Creasman WT, Mutch DG, Mannel RS, Tewari KS, eds. DiSaia and Creasman Clinical Gynecologic Oncology. 10th ed. Philadelphia, PA: Elsevier; 2023:chap 10.
Fletcher CDM. Tumors of the female genital tract. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 5th ed. Philadelphia, PA: Elsevier; 2021:chap 13.
Smith RP. Sertoli-Leydig cell tumor (arrhenoblastoma). In: Smith RP, ed. Netter's Obstetrics & Gynecology. 4th ed. Philadelphia, PA: Elsevier; 2024:chap 165.